Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to establish the performance of an assay that detects mRNA transcript levels in patients diagnosed with CML. The study is conducted at locations within the United States. Testing is performed on peripheral blood specimens provided by eligible enrolled patients. Results from this study will not be used for patient management decisions.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Primary Enrollment | Initial enrollment of patients with history of CML |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Xpert BCR-ABL Ultra | Device | Semi-quantitation of BCR-ABL transcript in patients that have been previously diagnosed with CML |
|
| Measure | Description | Time Frame |
|---|---|---|
| Method comparison to an on-market molecular diagnostic assay | Comparison of Xpert to an on-market test for the quantitation of BCR-ABL | Baseline = testing upon enrollment |
Not provided
Not provided
Inclusion Criteria:
prospective specimens:
frozen specimens:
Exclusion Criteria:
prospective specimens:
frozen specimens: • Specimen previously enrolled
Not provided
Not provided
Males and females at least 18 years of age who were previously diagnosed with CML from primary care clinics.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Broward Oncology Associates | Fort Lauderdale | Florida | 33308 | United States | ||
| St. Alphonsus Regional Medical Center |
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Sep 3, 2024 | |
| Reset | Nov 14, 2024 | |
| Release | Mar 7, 2025 | |
| Reset | Mar 26, 2025 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Sep 3, 2024 | Nov 14, 2024 | |||
| Mar 7, 2025 |
| ID | Term |
|---|---|
| D015464 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
| ID | Term |
|---|---|
| D007951 | Leukemia, Myeloid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Boise |
| Idaho |
| 83706 |
| United States |
| WJB Dorn VA Medical Center | Columbia | South Carolina | 29209 | United States |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | United States |
| United Hospital Center | Bridgeport | West Virginia | 26330 | United States |
| St. Mary's Medical Center | Huntington | West Virginia | 25702 | United States |
| Marshfield Clinic | Marshfield | Wisconsin | 54449 | United States |
| Mar 26, 2025 |
| D009196 |
| Myeloproliferative Disorders |
| D001855 | Bone Marrow Diseases |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |